Strategics add to Akili's series B round

In an extension of its series B round, Akili Interactive Labs Inc. (Boston, Mass.) raised $11.9 million from new investors Merck Ventures BV and Amgen Ventures, as well as existing investors. The extension brings the round's total to $42.4 million.

In January, Akili said it raised $30.5 million from a syndicate that included Jazz Venture Partners, Canepa Advanced Healthcare Fund and PureTech Health plc (LSE:PRTC) (see BioCentury Extra, Jan. 22). ...